Text Size

Quality Project to Evaluate and Validate the FAST-O Rating Scale

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00913731
First received: June 2, 2009
Last updated: October 28, 2009
Last verified: October 2009
History of Changes
  Purpose

The purpose of this project is to test the reliability of the FAST-O Rating Scale in patients at acute wards or psychiatric intensive care units.


Condition
Acute Psychotic Symptoms

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Quality Project to Evaluate and Validate the FAST-O Rating Scale (Fast ASessment in Acute Treatment of Psychosis-Observation)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Reliability test of the FAST-O rating scale based on observational symptom ratings of patients with acute psychotic diseases [ Time Frame: Each patients symtoms will be rated on 2 occasions, by 2-3 raters, each. First is made within 24 hrs of admission to acute psychiatric care, secondis made 14 +/- 2 days after admittance, or earlier if the patient is discharged. ] [ Designated as safety issue: No ]

Enrollment: 111
Study Start Date: May 2009
Study Completion Date: October 2009
Groups/Cohorts
psychotic patients
psychotic patients, acute ward, symptom rating scale.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with acute psychotic symptoms attending the acute ward or psychiatric intensive care unit

Criteria

Inclusion Criteria:

  • Patients with acute psychotic symptoms attending the acute ward or psychiatric intensive care unit

Exclusion Criteria:

  • Not applicable
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00913731

Locations
Sweden
Research Site
Helsingborg, Sweden
Research Site
Kristianstad, Sweden
Research Site
Lund, Sweden
Research Site
Malmo, Sweden
Research Site
Ystad, Sweden
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Eva Dencker Vansvik Medical Department
Principal Investigator: Eva Lindström Rättspsyk, UMAS, Malmö
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00913731     History of Changes
Other Study ID Numbers: NIS-NSE-DUM-2008/1
Study First Received: June 2, 2009
Last Updated: October 28, 2009
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by AstraZeneca:
Psychotic symptom assessments
Observational assessments of patients with acute psychotic symptoms

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on June 18, 2013